Overview

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Talimogene laherparepvec